This Was the World’s First Published Study Assessing MDMA-Assisted Psychotherapy as a Treatment for Addiction Toronto, Ontario–(Newsfile Corp. – September 23, 2021) – Awakn Life Sciences Corp., (NEO: AWKN) (OTCQB: AWKNF) (FSE: 954) (Awakn) a biotechnology company developing and delivering psychedelic therapeutics to treat addiction, announced today that it has acquired the exclusive rights to the…


Previous articleMindMed and Liechti Lab Provide Results from their Psilocybin R&D Collaboration
Next articlePTSF78 – Navigating the Vast Psychedelic Space: Where Do You Fit In?